From Lab to Clinic: Effect of Academia–Industry Collaboration Characteristics on Oncology Phase 1 Trial Entry
ABSTRACT This study investigated the success rate of Phase 1 clinical trial entry and the factors influencing it in oncology projects involving academia–industry collaboration during the discovery and preclinical stages. A total of 344 oncology projects in the discovery stage and 360 in the preclini...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Clinical and Translational Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/cts.70135 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832589764888363008 |
|---|---|
| author | Wonseok Yang Sang‐Won Lee |
| author_facet | Wonseok Yang Sang‐Won Lee |
| author_sort | Wonseok Yang |
| collection | DOAJ |
| description | ABSTRACT This study investigated the success rate of Phase 1 clinical trial entry and the factors influencing it in oncology projects involving academia–industry collaboration during the discovery and preclinical stages. A total of 344 oncology projects in the discovery stage and 360 in the preclinical stage, initiated through collaborations with universities or hospitals between 2015 and 2019, were analyzed. The Phase 1 clinical trial entry success rates for oncology collaborative projects were 9.9% from the discovery stage and 24.2% from the preclinical stage. For discovery stage contracts, strong statistical significance was observed for contract type (co‐development OR 16.45, p = 0.008; licensing OR 42.43, p = 0.000) and technology (cell or gene therapy OR 3.82, p = 0.008). In contrast, for preclinical stage contracts, significant changes were noted for cancer type (blood cancer OR 2.24, p = 0.004), while the year of contract signing showed a relatively weak statistical significance (OR 1.24, p = 0.021). No significant changes were observed concerning partner firm size and the partnership territory. This study sheds light on how the characteristics of partnerships influence the success rates of early‐phase research, providing valuable insights for future strategic planning in oncology drug development. |
| format | Article |
| id | doaj-art-53f9c191f0f240cc9dffd65462374d96 |
| institution | Kabale University |
| issn | 1752-8054 1752-8062 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Translational Science |
| spelling | doaj-art-53f9c191f0f240cc9dffd65462374d962025-01-24T08:17:46ZengWileyClinical and Translational Science1752-80541752-80622025-01-01181n/an/a10.1111/cts.70135From Lab to Clinic: Effect of Academia–Industry Collaboration Characteristics on Oncology Phase 1 Trial EntryWonseok Yang0Sang‐Won Lee1School of Pharmacy Sungkyunkwan University Suwon Gyeonggi‐do Republic of KoreaSchool of Pharmacy Sungkyunkwan University Suwon Gyeonggi‐do Republic of KoreaABSTRACT This study investigated the success rate of Phase 1 clinical trial entry and the factors influencing it in oncology projects involving academia–industry collaboration during the discovery and preclinical stages. A total of 344 oncology projects in the discovery stage and 360 in the preclinical stage, initiated through collaborations with universities or hospitals between 2015 and 2019, were analyzed. The Phase 1 clinical trial entry success rates for oncology collaborative projects were 9.9% from the discovery stage and 24.2% from the preclinical stage. For discovery stage contracts, strong statistical significance was observed for contract type (co‐development OR 16.45, p = 0.008; licensing OR 42.43, p = 0.000) and technology (cell or gene therapy OR 3.82, p = 0.008). In contrast, for preclinical stage contracts, significant changes were noted for cancer type (blood cancer OR 2.24, p = 0.004), while the year of contract signing showed a relatively weak statistical significance (OR 1.24, p = 0.021). No significant changes were observed concerning partner firm size and the partnership territory. This study sheds light on how the characteristics of partnerships influence the success rates of early‐phase research, providing valuable insights for future strategic planning in oncology drug development.https://doi.org/10.1111/cts.70135academia‐industry collaborationclinical trial entrycollaboration characteristicsoncologyprobability of success |
| spellingShingle | Wonseok Yang Sang‐Won Lee From Lab to Clinic: Effect of Academia–Industry Collaboration Characteristics on Oncology Phase 1 Trial Entry Clinical and Translational Science academia‐industry collaboration clinical trial entry collaboration characteristics oncology probability of success |
| title | From Lab to Clinic: Effect of Academia–Industry Collaboration Characteristics on Oncology Phase 1 Trial Entry |
| title_full | From Lab to Clinic: Effect of Academia–Industry Collaboration Characteristics on Oncology Phase 1 Trial Entry |
| title_fullStr | From Lab to Clinic: Effect of Academia–Industry Collaboration Characteristics on Oncology Phase 1 Trial Entry |
| title_full_unstemmed | From Lab to Clinic: Effect of Academia–Industry Collaboration Characteristics on Oncology Phase 1 Trial Entry |
| title_short | From Lab to Clinic: Effect of Academia–Industry Collaboration Characteristics on Oncology Phase 1 Trial Entry |
| title_sort | from lab to clinic effect of academia industry collaboration characteristics on oncology phase 1 trial entry |
| topic | academia‐industry collaboration clinical trial entry collaboration characteristics oncology probability of success |
| url | https://doi.org/10.1111/cts.70135 |
| work_keys_str_mv | AT wonseokyang fromlabtocliniceffectofacademiaindustrycollaborationcharacteristicsononcologyphase1trialentry AT sangwonlee fromlabtocliniceffectofacademiaindustrycollaborationcharacteristicsononcologyphase1trialentry |